MEGHNAD BHOWMİCK, FARAH AUCKBARALLEE, PAGE EDGAR, AMİTABHA RAY, SUBHAJİT DASGUPTA
Experimental and Clinical Transplantation - 2016;14(1):17-21
Successful attenuation of allograft rejection rate is amajor clinical aspect in transplant. The CD52 binding monoclonal antibody CAMPATH1 or alemtuzumab, in this aspect, shows a promise as an effective immunomodifier. This humanized monoclonal anti body efficiently depletes CD52-bearing mature B- and T lymphocytes from circulation and thereby causes transient lymphopenia, a condition for generalized immunosuppression. Alemtuzumab is an approved drug for the treatment of B cell chronic lymphocytic leukemia. However, its implication in transplant as nonsteroidal drug is a growing area of investigation. Here, we provided a brief account on alemtuzumab as an immunomodifier in allotrans plant.
